Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer
Cancers · 01.06.2026 · 18 (11) · 1799
DOI: 10.3390/cancers18111799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 01.06.2026. Verfasst von Cesare Guida und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiotherapy Complex Unit, Ospedale del Mare, Azienda Sanitaria Locale Napoli 1 Centro, 80147 Napoli, Italy. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Prostate cancer (PCa) is biologically heterogeneous, requiring management strategies that balance oncologic benefit with preservation of quality of life. Prostate-specific membrane antigen (PSMA) has emerged as a key theranostic biomarker enabling highly sensitive molecular imaging and targeted therapy.
Purpose
The present manuscript aims to summarize the clinical role of PSMA-PET/CT in PCa across staging, treatment selection, and response assessment, with a special focus on its contribution to personalized management. Key Findings: PSMA-PET/CT demonstrates superior accuracy compared with conventional imaging, frequently leading to stage migration and changes in therapeutic strategy. It improves detection of metastatic and recurrent disease, guides selection for systemic and PSMA-targeted therapies, and supports metastasis-directed treatment in oligometastatic settings, potentially delaying androgen-deprivation therapy and preserving quality of life. Additionally, PSMA-PET enhances intra-prostatic lesion delineation for focal therapies and radiotherapy planning. Limitations include reduced sensitivity for very small lesions, possible false positives, variability among tracers, and issues related to access and standardization.
Conclusions
PSMA-PET/CT is a cornerstone of precision imaging in PCa, enabling more individualized treatment decisions across the disease continuum. Ongoing studies will further define its long-term clinical impact and integration into routine care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiotherapy Complex Unit, Ospedale del Mare, Azienda Sanitaria Locale Napoli 1 Centro, 80147 Napoli, Italy.
- Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
- Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
- Medicina Futura, 80143 Napoli, Italy.
- Oncology Complex Unit, Santa Maria delle Grazie Hospital, Azienda Sanitaria Locale Napoli 2 Nord, 80078 Pozzuoli, Italy.
- Interuniversity Research Center for Sustainability (CIRPS), 00038 Rome, Italy.
ORCID-Profile: Laura Evangelista, Marco Spadafora, Gaetano Facchini, Luigi Mansi
Zitieren
APA
Guida, C., Evangelista, L., Spadafora, M., Facchini, G., & Mansi, L. (2026). Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer. Cancers, 18(11), 1799. https://doi.org/10.3390/cancers18111799
Vancouver
Guida C, Evangelista L, Spadafora M, Facchini G, Mansi L. Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer. Cancers. 2026;18(11):1799. doi:10.3390/cancers18111799
BibTeX
@article{Guida2026,
author = {Guida, Cesare and Evangelista, Laura and Spadafora, Marco and Facchini, Gaetano and Mansi, Luigi},
title = {Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {11},
pages = {1799},
doi = {10.3390/cancers18111799}
}
EUVIMED